瑞聯新材(688550.SH):終止部分募集資金投資項目
格隆匯1月6日丨瑞聯新材(688550.SH)公佈,公司於2025年1月6日召開第三屆董事會第十九次會議及第三屆監事會第十九次會議,審議通過了《關於終止部分募集資金投資項目的議案》,同意公司終止高端液晶顯示材料生產項目(稱“液晶項目”)和科研檢測中心項目,項目已簽訂合同待支付尾款金額共計1,814.14萬元,剩餘募集資金21,865.15萬元(包含募集資金利息收入及理財收益)仍將存放於原募集資金專用賬户並按照公司相關管理規定做好募集資金管理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.